Dupilumab Holds Up Over 52 Weeks in Prurigo Nodules

Fifty-two weeks of real-world follow-up is the headline number. That is how long researchers tracked prurigo nodularis patients on dupilumab in the prospective, multicenter BioDay registry — and the results appear in the Journal of the American Academy of Dermatology, Volume 95, Issue 5, published November 2026.

The study comes at a moment when prurigo nodularis, a chronic condition marked by intensely itchy nodules, still lacks the depth of long-term evidence that psoriasis and atopic dermatitis enjoy. Real-world registries like BioDay exist precisely to close that gap between trial conditions and everyday clinics.

The paper is the work of a large Dutch research team led by Lian F. van der Gang and Marjolein S. de Bruin-Weller of University Medical Center Utrecht, alongside collaborators including Octavian Bacoş-Cosma, Marlies de Graaf, Laura Loman, Francine C. van Erp, Inge M. Haeck, and Marie-Louise A. Schuttelaar.

Why does 52 weeks matter?

Randomized trials answer whether a drug works. Registries answer whether it keeps working.

BioDay follows patients in routine care, not under protocol. That design captures the population dermatologists actually treat — comorbidities, missed doses, co-medications and all. A full year of follow-up covers the window where durability questions surface in chronic itch disorders.

The takeaway: this is effectiveness data, not just efficacy data.

What is dupilumab doing here?

Dupilumab is a monoclonal antibody blocking IL-4 and IL-13 signaling, already established in atopic dermatitis and approved for prurigo nodularis on the strength of pivotal trials — the PRIME and PRIME2 studies — which demonstrated significant itch reduction measured on the Worst Itch-Numeric Rating Scale.

The BioDay analysis asks the next question. Does the benefit persist, and does the safety profile stay clean, across a year of unselected real-world use?

That distinction — trial efficacy versus registry effectiveness — is the whole point of this publication.

How was the study built?

The design is prospective and multicenter. Patients receiving dupilumab for prurigo nodularis were enrolled across participating Dutch centers and followed for 52 weeks, with effectiveness and safety assessed over that period.

The author list spans allergists and dermatologists from several institutions, reflecting the multi-center recruitment that gives registry data their generalizability.

In plain words: this is one of the longer real-world looks at dupilumab in this hard-to-treat disease.

What should clinicians watch for?

For dermatologists managing prurigo nodularis, long-term dupilumab data inform counseling on persistence, safety monitoring and expected timelines of response. Registry findings also matter for payers weighing coverage decisions beyond the trial population.

The full effectiveness and safety results — including responder rates and adverse event profiles — are detailed in the published article, which readers should consult directly for the primary outcome numbers.

With the BioDay registry continuing to accrue follow-up, this 52-week readout likely sets the baseline for even longer-term analyses in the years ahead.